http://clinicaltrials.gov/ct2/show/NCT00503724 Neuro Oncology

For information on the following Clinical Trials, please contact the
Hematology, Oncology and Stem Cell Transplantation Department
at 773-880-4562 during 8:30 AM to 5:00 PM Central Standard Time.

  Newly Diagnosed Brain Tumors   Investigator 
     
  High-Grade Glioma and Brain Stem Glioma   
PBTC-021 A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas  Stewart Goldman, MD
     
  Medulloblastoma  
ACNS0331 A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial Stewart Goldman, MD
ACNS0332 Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients Stewart Goldman, MD
ACNS0334 A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate Stewart Goldman, MD
     
  Germ Cell Tumors  
ACNS0232 Radiotherapy Alone Vs. Chemotherapy Followed by Response-based Radiotherapy for Newly Diagnosed Primary CNS Germinoma Stewart Goldman, MD
     
  Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors (MPNST)  
CNS 1007 Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Unresectable Malignant Peripheral nerve Sheath Tumors Stewart Goldman, MD
     
  Low-Grade Glioma
Relapsed, Refractory or Progressive Brain Tumors  
ACNS0621 Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma Stewart Goldman, MD
ONC 0205  Anti-Angiogenic Chemotherapy: A Phase II Trial of Oral 5-Drug Regimen in Patients with Poor Prognosis, Relapsed or Progressive Cancer Stewart Goldman, MD
CNS 1100 A Phase I Study Using Submyeloablative Dosing of Intravenous Busulfan (Busulfex) for Refractory Brain Tumors Stewart Goldman, MD
PBTC-020 A Phase I Clinical Trial of AZD2171 in Children with Recurrent or Progressive Central Nervous System (CNS) Tumors Stewart Goldman, MD
PBTC-023 Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors Stewart Goldman, MD
PBTC-024 A Phase I Study of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies Stewart Goldman, MD
TRT-014 Multi-Center, Open-Label, Expanded Access Protocol for Humanized Monoclonal Antibody (Nimotuzumab) in Patients with Recurrent Brain Stem Tumors Stewart Goldman, MD
YMB1000-013 Phase 2 Study of Safety and Efficacy of Nimotuzumab (TheraCIM®) in Pediatric Patients with Recurrent Diffuse Intrinsic Pontine Glioma Stewart Goldman, MD
     
  Relapsed, Refractory or Progressive High-Grade Gliomas (including Brainstem Glioma)  
PBTC-023 Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors Stewart Goldman, MD
     
  Relapsed, Refractory or Progressive Low-Grade Glioma  
PBTC-022 Phase II Study of Bevacizumab Plus Irinotecan (Captosar) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas and Diffuse / Intrinsic Brain Stem Gliomas, Medulloblastomas and Ependymomas Stewart Goldman, MD
PBTC-023 Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors Stewart Goldman, MD
     
  Relapsed, Refractory or Progressive Ependymoma  
PBTC-022   
 Phase II Study of Bevacizumab Plus Irinotecan (Captosar) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas and Diffuse / Intrinsic Brain Stem Gliomas, Medulloblastomas and Ependymomas Stewart Goldman, MD
PBTC-023 Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors Stewart Goldman, MD
PBTC-024 A Phase I Study of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies Stewart Goldman, MD
   
Relapsed, Refractory or Progressive Medulloblastoma  
PBTC-022 Phase II Study of Bevacizumab Plus Irinotecan (Captosar) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas and Diffuse / Intrinsic Brain Stem Gliomas, Medulloblastomas and Ependymomas Stewart Goldman, MD
PBTC-023 Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors Stewart Goldman, MD
PBTC-024 A Phase I Study of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies Stewart Goldman, MD
     
  Neoplastic Meningitis  
PBTC-019  A Phase I Pharmacokinetic Optimal Dosing Study of Intrathecal Topotecan for Children with Neoplastic Meningitis Stewart Goldman, MD
     
  Brain Tumor Biology Studies  

Back to the top of the page